IMU Biosciences has secured a 53 million 40 million Series A fundraising round, bringing the total raised in the round to more than double the original amount. This huge vote of confidence highlights the faith the market has in IMUs AI-native strategy of the human immune system.
The new round was led by IQ Capital and Molten Ventures and included strong support from British Business Bank, Meltwind and other existing institutional investors. With this new injection of capital, IMU has now raised around 60m overall, making it the worlds leading high-resolution immune profiling platform.
From Academic Research to HD ImmunologyFounded on nearly a decade of pioneering research at the Francis Crick Institute and Kings College London, IMU Biosciences aims to solve a fundamental problem in modern medicine: while the immune system is the gatekeeper of all human health, it remains notoriously difficult to measure with precision.
